Trials / Completed
CompletedNCT00296504
A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects
An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 753 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.
Detailed description
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fosamprenavir (GW433908) | |
| DRUG | ritonavir |
Timeline
- Start date
- 2001-11-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2006-02-27
- Last updated
- 2013-04-19
- Results posted
- 2011-11-08
Locations
24 sites across 8 countries: United States, Brazil, Chile, France, Italy, Portugal, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00296504. Inclusion in this directory is not an endorsement.